GlycoX

Company Bio

Founders

LvlUp insightsGenerated from LvlUp’s portfolio data and the company’s own updates
Similar companies

More in the LvlUp portfolio

See all →

Building something ambitious?

LvlUp Ventures backs founders from first check to late stage.

Apply for funding
Matias Gonzalez, Robson Olivoto
Seed
United States
BioTech, DeepTech, HealthTech, FoodTech
GlycoX monetizes through three parallel paths that do not depend on each other. The pharmaceutical program enters via FDA orphan designation for lipodystrophy, generating licensing and royalty revenue, then expands into diabetes and obesity, two of the largest drug markets in the world. A supplement channel reaches consumers without waiting for an IND. A veterinary and agricultural market addresses metabolic dysfunction in companion animals and livestock. A fourth path licenses the formulation as an ingredient to food companies. One underlying biology. Four revenue streams. Each one opening on a different timeline.

GlycoX reverses metabolic disease at its root through four independent mechanisms in one oral platform. We enter via lipodystrophy, earning FDA orphan exclusivity, then expand to the 1 billion people living with diabetes and obesity who need an affordable, accessible option. No needle required.